Systematic associations between germ-line mutations and human cancers
KeywordGerm-line mutations; Human cancers; Gene mutations; Chromosomes; Pathways; Big data; Cancer mutation; Cancer map; Gene mutation interconnections; Gene mutation distribution; Bioinformatics
Rights© 2016 Inderscience Enterprises Ltd. Reproduced in accordance with the publisher's self-archiving policy.
MetadataShow full item record
AbstractThe revolution in Big Data has opened the gate for new research challenges in biomedical science. The aim of this study was to investigate whether germ-line gene mutations are a significant factor in 29 major primary human cancers. Using data obtained from multiple biological databases, we identified 424 genes from 8879 cancer mutation records. By integrating these gene mutation records a human cancer map was constructed from which several key results were obtained. These include the observations that missense/nonsense and regulatory mutations might play central role in connecting cancers/genes, and tend to be distributed in all chromosomes. This suggests that, of all mutation classes missense/nonsense and regulatory mutation classes are over-expressed in human genome and so are likely to have a significant impact on human cancer aetiology and pathomechanism. This offers new insights into how the distribution and interconnections of gene mutations influence the development of cancers.
CitationAl-Shammari M, Tobin DJ and Peng Y (2016) Systematic associations between germ-line mutations and human cancers. International Journal of Computational Biology and Drug Design. 9(1-2): 135-148.
Link to publisher’s versionhttp://www.inderscienceonline.com/doi/abs/10.1504/IJCBDD.2016.074980
Showing items related by title, author, creator and subject.
Biallelic Mutations in the Autophagy Regulator DRAM2 Cause Retinal Dystrophy with Early Macular InvolvementEl-Asrag, M.E.; Sergouniotis, P.I.; McKibbin, M.; Plagnol, V.; Sheridan, E.; Waseem, N.; Abdelhamed, Z.; McKeefry, Declan J.; Van Schil, K.; Poulter, J.A.; UK Inherited Retinal Disease Consortium; Johnson, C.A.; Carr, I.M.; Leroy, B.P.; Baere, E. de; Inglehearn, C.F.; Webster, A.R.; Toomes, C.l.; Ali, M. (2015-06)Retinal dystrophies are an overlapping group of genetically heterogeneous conditions resulting from mutations in more than 250 genes. Here we describe five families affected by an adult-onset retinal dystrophy with early macular involvement and associated central visual loss in the third or fourth decade of life. Affected individuals were found to harbor disease-causing variants in DRAM2 (DNA-damage regulated autophagy modulator protein 2). Homozygosity mapping and exome sequencing in a large, consanguineous British family of Pakistani origin revealed a homozygous frameshift variant (c.140delG [p.Gly47Valfs∗3]) in nine affected family members. Sanger sequencing of DRAM2 in 322 unrelated probands with retinal dystrophy revealed one European subject with compound heterozygous DRAM2 changes (c.494G>A [p.Trp165∗] and c.131G>A [p.Ser44Asn]). Inspection of previously generated exome sequencing data in unsolved retinal dystrophy cases identified a homozygous variant in an individual of Indian origin (c.64_66del [p.Ala22del]). Independently, a gene-based case-control association study was conducted via an exome sequencing dataset of 18 phenotypically similar case subjects and 1,917 control subjects. Using a recessive model and a binomial test for rare, presumed biallelic, variants, we found DRAM2 to be the most statistically enriched gene; one subject was a homozygote (c.362A>T [p.His121Leu]) and another a compound heterozygote (c.79T>C [p.Tyr27His] and c.217_225del [p.Val73_Tyr75del]). DRAM2 encodes a transmembrane lysosomal protein thought to play a role in the initiation of autophagy. Immunohistochemical analysis showed DRAM2 localization to photoreceptor inner segments and to the apical surface of retinal pigment epithelial cells where it might be involved in the process of photoreceptor renewal and recycling to preserve visual function.
Rapid endocytosis provides restricted somatic expression of a K+ channel in central neuronsCorrêa, Sonia A.L.; Muller, Jurgen; Collingridge, G.L.; Marrion, N.V. (2009)Trafficking motifs present in the intracellular regions of ion channels affect their subcellular location within neurons. The mechanisms that control trafficking to dendrites of central neurons have been identified, but it is not fully understood how channels are localized to the soma. We have now identified a motif within the calcium-activated potassium channel K(Ca)2.1 (SK1) that results in somatic localization. Transfection of hippocampal neurons with K(Ca)2.1 subunits causes expression of functional channels in only the soma and proximal processes. By contrast, expressed K(Ca)2.3 subunits are located throughout the processes of transfected neurons. Point mutation of K(Ca)2.1 within this novel motif to mimic a sequence present in the C-terminus of K(Ca)2.3 causes expression of K(Ca)2.1 subunits throughout the processes. We also demonstrate that blocking of clathrin-mediated endocytosis causes K(Ca)2.1 subunit expression to mimic that of the mutated subunit. The role of this novel motif is therefore not to directly target trafficking of the channel to subcellular compartments, but to regulate channel location by subjecting it to rapid clathrin-mediated endocytosis.
The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53Thomas, A.; Perry, T.; Berhane, S.; Oldreive, C.; Zlatanou, A.; Williams, L.R.; Weston, V.J.; Stankovic, T.; Kearns, P.; Pors, Klaus; Grand, R.J.; Stewart, G.S. (2015-06-01)Topoisomerase inhibitors are in common use as chemotherapeutic agents although they can display reduced efficacy in chemotherapy-resistant tumours, which have inactivated DNA damage response (DDR) genes, such as ATM and TP53. Here, we characterise the cellular response to the dual-acting agent, Alchemix (ALX), which is a modified anthraquinone that functions as a topoisomerase inhibitor as well as an alkylating agent. We show that ALX induces a robust DDR at nano-molar concentrations and this is mediated primarily through ATR- and DNA-PK- but not ATM-dependent pathways, despite DNA double strand breaks being generated after prolonged exposure to the drug. Interestingly, exposure of epithelial tumour cell lines to ALX in vitro resulted in potent activation of the G2/M checkpoint, which after a prolonged arrest, was bypassed allowing cells to progress into mitosis where they ultimately died by mitotic catastrophe. We also observed effective killing of lymphoid tumour cell lines in vitro following exposure to ALX, although, in contrast, this tended to occur via activation of a p53-independent apoptotic pathway. Lastly, we validate the effectiveness of ALX as a chemotherapeutic agent in vivo by demonstrating its ability to cause a significant reduction in tumour cell growth, irrespective of TP53 status, using a mouse leukaemia xenograft model. Taken together, these data demonstrate that ALX, through its dual action as an alkylating agent and topoisomerase inhibitor, represents a novel anti-cancer agent that could be potentially used clinically to treat refractory or relapsed tumours, particularly those harbouring mutations in DDR genes.